ConvaTec Group (OTCMKTS:CNVVY) Price Target Increased to GBX 300 by Analysts at Barclays

ConvaTec Group (OTCMKTS:CNVVY – Get Rating) had its price objective upped by stock analysts at Barclays from GBX 295 ($3.70) to GBX 300 ($3.76) in a note issued to investors on Friday, The Fly reports.

Several other analysts have also commented on CNVVY. Sanford C. Bernstein initiated coverage on ConvaTec Group in a report on Tuesday, March 7th. They set an “outperform” rating for the company. JPMorgan Chase & Co. increased their price target on ConvaTec Group from GBX 281 ($3.52) to GBX 305 ($3.82) in a research report on Friday, March 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $267.50.

ConvaTec Group Stock Performance

Shares of CNVVY opened at $10.69 on Friday. ConvaTec Group has a 12 month low of $8.69 and a 12 month high of $12.23. The stock has a fifty day moving average price of $10.68 and a 200-day moving average price of $11.01.

About ConvaTec Group

(Get Rating)

ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions.